Literature DB >> 18041087

Primary central nervous system vasculitis: progress and questions.

Leonard H Calabrese, Eamonn S Molloy, Aneesh B Singhal.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 18041087     DOI： 10.1002/ana.21283

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  6 in total

1.  [Reversible cerebral vasoconstriction syndrome vs cerebral vasculitis? On the importance and difficulty of differentiating].

Authors:  M Krämer; P Berlit
Journal:  Nervenarzt       Date:  2011-04       Impact factor: 1.214

2.  Primary central nervous system vasculitis: clinical experiences with 21 new European cases.

Authors:  Markus Kraemer; Peter Berlit
Journal:  Rheumatol Int       Date:  2009-12-19       Impact factor: 2.631

Review 3.  Immunomodulatory therapies in neurologic critical care.

Authors:  Logan M McDaneld; Jeremy D Fields; Dennis N Bourdette; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-09-23       Impact factor: 3.210

4.  A 25-year-old man with progressive left-sided weakness and a mass lesion on brain imaging.

Authors:  T Franco; C Roque; S Khorasanizadeh; L D McCullough
Journal:  J Postgrad Med       Date:  2009 Jul-Sep       Impact factor: 1.476

5.  Central nervous system vasculitis: still more questions than answers.

Authors:  Marco A Alba; Georgina Espígol-Frigolé; Sergio Prieto-González; Itziar Tavera-Bahillo; Ana García-Martínez; Montserrat Butjosa; José Hernández-Rodríguez; Maria C Cid
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363

6.  Extended stereotactic brain biopsy in suspected primary central nervous system angiitis: good diagnostic accuracy and high safety.

Authors:  Veit Michael Stoecklein; Lars Kellert; Maximilian Patzig; Clemens Küpper; Armin Giese; Viktoria Ruf; Jonathan Weller; Friedrich-Wilhelm Kreth; Florian Schöberl
Journal:  J Neurol       Date:  2020-08-19       Impact factor: 4.849
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.